111 related articles for article (PubMed ID: 23225231)
21. Biomarker response and therapy prediction in renal denervation therapy - the role of MR-proadrenomedullin in a multicenter approach.
Neumann JT; Schwerg M; Dörr O; Mortensen K; Franzen K; Zeller T; Ojeda F; Blankenberg S; Hamm C; Nef H; Stangl V; Möckel M; Sydow K
Biomarkers; 2017; 22(3-4):225-231. PubMed ID: 27153479
[TBL] [Abstract][Full Text] [Related]
22. The midregional portion of proadrenomedullin is an independent predictor of left ventricular mass index in hypertension.
Bhandari SS; Davies JE; Struck J; Ng LL
Metabolism; 2010 Jan; 59(1):7-13. PubMed ID: 19716143
[TBL] [Abstract][Full Text] [Related]
23. High plasma mid-regional pro-adrenomedullin levels in children with severe dengue virus infections.
Michels M; Djamiatun K; Faradz SM; Koenders MM; de Mast Q; van der Ven AJ
J Clin Virol; 2011 Jan; 50(1):8-12. PubMed ID: 20952250
[TBL] [Abstract][Full Text] [Related]
24. Relationship between plasma mid-regional pro-adrenomedullin level and resistance to antihypertensive therapy in stable kidney transplant recipients.
Suzuki Y; Itoh H; Katagiri F; Sato F; Kawasaki K; Sato Y; Sato Y; Mimata H; Takeyama M
Peptides; 2013 Oct; 48():45-8. PubMed ID: 23954711
[TBL] [Abstract][Full Text] [Related]
25. Sensitive and selective quantification of mid-regional proadrenomedullin in human plasma using ultra-performance liquid chromatography coupled with tandem mass spectrometry.
Iwao M; Suzuki Y; Tanaka R; Koyama T; Ozaki E; Nakata T; Aoki K; Fukuda A; Sato Y; Kuriyama N; Fukunaga N; Sato F; Katagiri F; Ohno K; Shibata H; Mimata H; Itoh H
J Pharm Biomed Anal; 2020 May; 183():113168. PubMed ID: 32062014
[TBL] [Abstract][Full Text] [Related]
26. Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients.
Struck J; Tao C; Morgenthaler NG; Bergmann A
Peptides; 2004 Aug; 25(8):1369-72. PubMed ID: 15350706
[TBL] [Abstract][Full Text] [Related]
27. Plasma Adrenomedullin, Allelic Variations in the ADM Gene, and Risk for Lower-Limb Amputation in People With Type 2 Diabetes.
Potier L; Mohammedi K; Saulnier PJ; Fumeron F; Halimi JM; Venteclef N; Marre M; Hadjadj S; Roussel R; Velho G
Diabetes Care; 2022 Jul; 45(7):1631-1639. PubMed ID: 35583678
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic performance of mid-regional pro-adrenomedullin as an analyte for the exclusion of left ventricular dysfunction.
Elmas E; Lang S; Dempfle CE; Kälsch T; Papassotiriou J; Morgenthaler NG; Borggrefe M; Brueckmann M
Int J Cardiol; 2008 Aug; 128(1):107-11. PubMed ID: 17698224
[TBL] [Abstract][Full Text] [Related]
29. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397].
Christ-Crain M; Morgenthaler NG; Stolz D; Müller C; Bingisser R; Harbarth S; Tamm M; Struck J; Bergmann A; Müller B
Crit Care; 2006; 10(3):R96. PubMed ID: 16805922
[TBL] [Abstract][Full Text] [Related]
30. Plasma mid-regional pro-adrenomedullin: A biomarker of the ischemic penumbra in hyperacute stroke.
Ishiyama H; Tanaka T; Saito S; Koyama T; Kitamura A; Inoue M; Fukushima N; Morita Y; Koga M; Toyoda K; Kuriyama N; Urushitani M; Ihara M
Brain Pathol; 2023 Mar; 33(2):e13110. PubMed ID: 35916272
[TBL] [Abstract][Full Text] [Related]
31. Association between Mid-Regional Proadrenomedullin Levels and Progression of Deep White Matter Lesions in the Brain Accompanying Cognitive Decline.
Kuriyama N; Ihara M; Mizuno T; Ozaki E; Matsui D; Watanabe I; Koyama T; Kondo M; Tokuda T; Tamura A; Yamada K; Akazawa K; Takeda K; Takada A; Mizuno S; Nakagawa M; Watanabe Y
J Alzheimers Dis; 2017; 56(4):1253-1262. PubMed ID: 28234256
[TBL] [Abstract][Full Text] [Related]
32. Stable-State Midrange Proadrenomedullin Is Associated With Severe Exacerbations in COPD.
Citgez E; Zuur-Telgen M; van der Palen J; van der Valk P; Stolz D; Brusse-Keizer M
Chest; 2018 Jul; 154(1):51-57. PubMed ID: 29475034
[TBL] [Abstract][Full Text] [Related]
33. Adrenomedullin and endothelin-1 are related to inflammation in chronic heart failure.
Gombos T; Förhécz Z; Pozsonyi Z; Wallentin S; Papassotiriou J; Kunde J; Morgenthaler NG; Jánoskuti L; Prohászka Z
Inflamm Res; 2009 Jun; 58(6):298-305. PubMed ID: 19212702
[TBL] [Abstract][Full Text] [Related]
34. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure.
Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
J Card Fail; 2013 Jan; 19(1):31-9. PubMed ID: 23273592
[TBL] [Abstract][Full Text] [Related]
35. Stable-State Midrange-Proadrenomedullin Level Is a Strong Predictor of Mortality in Patients With COPD.
Zuur-Telgen MC; Brusse-Keizer MG; VanderValk PD; van der Palen J; Kerstjens HA; Hendrix MG
Chest; 2014 Mar; 145(3):534-541. PubMed ID: 27845633
[TBL] [Abstract][Full Text] [Related]
36. Midregional proadrenomedullin predicts reduced blood pressure and glucose elevation over time despite enhanced progression of obesity markers.
Ohlsson T; Nilsson PM; Persson M; Melander O
J Hypertens; 2019 Mar; 37(3):590-595. PubMed ID: 30540625
[TBL] [Abstract][Full Text] [Related]
37. Novel biomarkers in acute heart failure: MR-pro-adrenomedullin.
Peacock WF
Clin Chem Lab Med; 2014 Oct; 52(10):1433-5. PubMed ID: 24756062
[TBL] [Abstract][Full Text] [Related]
38. Comparison of long-term prognostic value of N-terminal-proBNP and midregional-pro-adrenomedullin in patients with acute myocardial infarction.
Walter T; Brueckmann M; Lang S; Sauer T; Fiedler E; Papassotiriou J; Behnes M; Elmas E; Borggrefe M; Bertsch T
Clin Lab; 2010; 56(7-8):303-9. PubMed ID: 20857894
[TBL] [Abstract][Full Text] [Related]
39. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure.
Gegenhuber A; Struck J; Dieplinger B; Poelz W; Pacher R; Morgenthaler NG; Bergmann A; Haltmayer M; Mueller T
J Card Fail; 2007 Feb; 13(1):42-9. PubMed ID: 17339002
[TBL] [Abstract][Full Text] [Related]
40. Association between MR-proADM concentration and treatment intensity of antihypertensive agents in chronic kidney disease patients with insufficient blood pressure control.
Iwao M; Tanaka R; Suzuki Y; Nakata T; Aoki K; Fukuda A; Fukunaga N; Tatsuta R; Ohno K; Shibata H; Itoh H
Sci Rep; 2021 Nov; 11(1):21931. PubMed ID: 34754024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
